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Background/aim: IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1 (G>A), IVSII-745 (C>G), IVSI-1 (G>A), and HbS are mutations covering
76% of all the β-globin mutations in the Turkish population. In this study, our aim is to develop a reliable, fast, real-time kit for these
mutations using the TaqMan probe method.
Materials and methods: This study included 100 individuals with beta-thalassemia or sickle cell anemia who had unknown mutations,
and 21 controls with known mutations.
Results: We designed a kit containing the IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1 (G>A), IVSII-745 (C>G), IVSI-1 (G>A), and HbS
mutations by using the real-time PCR method. One hundred patients were studied with our developed TaqMan real-time PCR kit.
Of these patients, 73 (73%) were identified with the beta gene mutation. Among those 73 patients, 16 were homozygous, 54 were
heterozygous, and 3 were compound heterozygous.
Conclusion: This reliable kit provided rapid diagnosis including 76% of the β-thalassemia mutations in Turkey.
Key words: Beta-thalassemia, HbS, β-thalassemia screening kit, mutation

1. Introduction
Beta-thalassemia is the most common autosomal recessive
single-gene disorder in the world (1). According to the
World Health Organization, abnormal hemoglobin
frequency is at 7% globally (2). Mutations in the HBB gene
lead to diseases such as sickle cell anemia, β-thalassemia,
and other abnormal hemoglobins. To date, approximately
200 different mutations have been reported in the β-globin
gene (3).
Although the Turkish population has a reported
prevalence of 2.1%, these mutations are as high as 13%
in other regions (4–6). In Turkey, more than 35 different
β-thalassemia-causing mutations have been described
by molecular analysis (7,8). Most commonly, β-globin
gene mutations are observed in the Turkish population,
including IVSI-110 (G>A) (40.88%), IVSI-6 (10.3%),
IVSII-1 (8.1%), IVSII-745 (6.2%), IVSI-1 (5.7%), and HbS
(4.9%), covering 71.18% of all β-globin gene mutations.
Along with the HbS mutation, this rate increases to 76% in
the Turkish population (7,9).
* Correspondence: ferdaep@yahoo.com

Thalassemia mutation screening can be performed
prenatally and postnatally. Current conventional
diagnostic methods, such as erythrocyte index and
morphology, Hb electrophoresis, HbA2 identification, and
identification of HbH inclusion bodies in erythrocytes,
provide the diagnosis, yet none can determine the
mutation (10,11). Most of the time, patients are able
to obtain an accurate diagnosis with the use of these
methods, yet it is still necessary to create molecular tests
for identification of carriers, silent carriers, and prenatal
cases. In addition to prenatal diagnosis, using the support
of clinical diagnoses with reliable laboratory results is very
important for patient follow-up, prognosis, and genetic
counseling (11). Molecular methods that are currently
used in the identification of thalassemia mutations
include oligonucleotide hybridization, restriction
endonuclease analysis, amplification refractory mutation
system (ARMS), temporal temperature gradient gel
electrophoresis, strip assay, LightCycler technology, and
DNA sequence analysis of the β-globin gene (9,10,12–15).
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In the past, malaria endemism in Mediterranean
countries was very high. It is known that in areas with
persistent malaria outbreaks, because the benign sickle trait
possesses resistance to malarial infection, heterozygous
individuals have a distinct advantage. This is why
individuals with heterozygous alleles are far more common
in these areas. Furthermore, the number of carriers
related to consanguineous marriage frequency in Turkey
is higher than in other countries. Considering the high
fertility rates in Turkey, high pregnancy rates for carriers
are to be expected. For the management of thalassemia, it
is necessary to develop rapid, easily applicable, relatively
inexpensive, and reliable new screening methods for the
most common mutations. For simultaneous screening of
multiple mutations, the real-time PCR method is a very
advantageous, easy, and reliable method of testing. It is
highly flexible in relation to mutation detection probe
preparation. Post-PCR processes, such as electrophoresis,
are not necessary.
In this study, our aim was to develop a new molecular
genetic analysis kit for screening common β-thalassemia
mutations and HbS, which are observed frequently in
Turkey.
2. Materials and methods
We defined six mutations covering 76% of all β-globin
mutations in Turkey, including IVSI-110 (G>A), IVSI-6
(T>C), IVSII-1 (G>A), IVSII-745 (C>G), IVSI-1 (G>A),
and HbS, in order to standardize a real-time (TaqMan)
PCR method.
Our control group included DNA samples from a total
of 21 patients. Eighteen of these patients have a disease
with already identified mutations, and three are healthy
individuals. These 21 individuals were selected from the
Department of Medical Biology and Genetics, Faculty of
Medicine, Akdeniz University, Antalya; Medical Genetics
Laboratory, Faculty of Medicine, İstanbul University,
İstanbul; and Medical Genetics Laboratory, Faculty of
Medicine, İnönü University, Malatya. Control DNA was
used for the validation of the developed kit and as an
external control for the test. Before starting the study,
we performed sequence analyses for all controls, which
included both affected and healthy individuals.
A total of 35 patients selected from the Ankara Provincial
Health Directorate Thalassemia Diagnosis Center were
found to be carriers or affected by β-thalassemia or sickle
cell anemia. Their conditions were diagnosed by using
hemoglobin electrophoresis and/or high-performance
liquid chromatography. Moreover, 65 patients were
found to be carriers or affected by β-thalassemia or
sickle cell anemia by using molecular genetic methods.
These patients were selected from the Medical Genetics
Laboratory, Faculty of Medicine, İstanbul University,
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İstanbul; Medical Faculty Laboratory, Ankara University,
Ankara; and Department of Medical Genetics, Adana
Numune Education and Research Hospital, Adana.
Informed consent from all participants and approval
from the Gazi University Local Ethics Committee (#3657)
were obtained.
2.1. DNA isolation
Approximately 5 mL of venous blood samples were drawn
from 35 patients and stored in EDTA tubes at 4 °C until
DNA isolations were performed. DNA isolation from the
blood samples was performed according to the instructions
of the Axygen DNA isolation kit. Obtained genomic DNA
was stored at –20 °C. The DNA samples of the 65 patients
and 21 controls were obtained from the centers mentioned
above.
2.2. Real-time PCR primers and probe design
We designed primers and TaqMan probes for each mutation
site, including IVSI-110 (G>A), IVSI-6 (T>C), IVSII-1
(G>A), IVSII-745 (C>G), IVSI-1 (G>A), and HbS (Table
1). The glucose-6-phosphate dehydrogenase (GAPDH)
gene was used as an internal control. The reporters and
repressors shown in Table 2 were used for the probes,
which were designed specifically for the mutation sites
and internal control regions. Allelic discrimination was
facilitated by software analysis of the fluorescence data.
3. Results
The results of the 100 patients studied by TaqMan realtime PCR are shown in Table 3. Although mutation was
detected in 73 of the total 100 patients, the remainder did
not have any of the mutations found in our panel. The
results of the 65 patients obtained from the previously
mentioned centers were confirmed by the results of the
laboratories that had initially conducted the tests.
We performed DNA sequencing analysis to confirm
our real-time PCR results. Therefore, we selected five
patients whose mutations had been described by each
of our mutation panels and six patients who had no
mutations. Known mutations that were not included in
our panel were detected in the sequencing results of these
six patients. The sequencing results of other patients were
compatible with our real-time study results, confirming
the accuracy of this method. All analysis results are shown
in Table 4.
4. Discussion
Hemoglobinopathies, which are among the most common
hereditary diseases, form a group of significant health
problems in Turkey. Sickle cell anemia and β-thalassemia
are the most common types of hemoglobinopathies found
in Turkey. β-Thalassemia is most frequently observed in
Mersin (13.6%), Antalya (13%), Hatay (10.6%), and Adana
(10%), all of which are located in the Mediterranean region
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Table 1. Pair of forward and reverse primers and probes.
Mutations region Primers

Probes

IVSI-110 (G>A)

Forward primer (normal)
Forward primer (mutant)
Reverse primer

CACTGACTCTCTCTGCCTATAG
CACTGACTCTCTCTGCCTATGA
ATCTGTCCACTCCTGATGCTGT

IVSI-1 (G>A)

Forward primer (normal)
Forward primer (mutant)
Reverse primer

AGGCCCTGGGCAGGTTAG
TGAGGCCCTGGGCAGATTTA
TGCTGGTGGTCTACCCTTGG

TCTGATAGGCACTGACTCTCTCTGCC

IVSI-6 (T>C)

Forward primer
Reverse primer (normal)
Reverse primer (mutant)

CCATGGTGCATCTGACTCCT
CTCAAGGTTACAAGACAGGTTTAAG
TCAAGGTTACAAGACAGGTTTAAG

TCTGCCGTTACTGCCCTGTGGGG

IVSII-745 (C>G)

Forward primer (normal)
Forward primer (mutant)
Reverse primer

GCTAATAGCAGCTACAATCCATC
GCTAATAGCAGCTACAATCCAAG
ACCTCTTATCTTCCTCCCACA

TGAGTCCAAGCTAGGCCCTTTTGCTA

IVSII-1 (G>A)

Forward primer
Reverse primer (normal)
Reverse primer (mutant)

CAAGAAAGTGCTCGGTGCCTTTA
GAGAGTCTATGGGACGCTTG
AGGAGTCTATGGGACGCTTG

Hb S [Glu-Val,
GAG-GTG]

Forward primer (normal)
Forward primer (mutant)
Reverse primer

CATGGTGCATCTGACTCCTTA
CATGGTGCATCTGACTCCTAT
TAGAAACTGGGCATGTGGAGAC

ATCAAGGTTACAAGACAGGTTTAAGGA

Internal control
primers

Forward primer
Reverse primer

TCCTGCACCACCAACTGCTTAG
GGGAAACTGTGGCGTGATG

AGGTCATCCATGACAACTTTGGYATCG

TTCCCACCCTTAGGCTGCTGGTG

ACAAGCTGCACGTGGATCCTGAGAA

Table 2. Reporters and repressors used for the probes.
5’ reporters

Probes

3’ repressors

IVSI-110 (G>A)

FAM

5’-TTC CCA CCC TTA GGC TGC TGG TG-3’

BHQ

IVSI-1 (G>A)

FAM

5’-TCT GAT AGG CAC TGA CTC TCT CTG CC-3’

BHQ

IVSI-6 (T>C)

FAM

5’-TCT GCC GTT ACT GCC CTG TGG GG-3’

BHQ

IVSII-745 (C>G)

FAM

5’-TGA GTC CAA GCT AGG CCC TTT TGC TA-3’

BHQ

IVSII-1 (G>A)

FAM

5’-ACA AGC TGC ACG TGG ATC CTG AGA A-3’

BHQ

HbS [Glu-Val, GAG-GTG]

FAM

5’-ATC AAG GTT ACA AGA CAG GTT TAA GGA-3’

BHQ

Internal control

JOE

5’-AGG TCA TCC ATG ACA ACT TTG GYA TCG-3’

TAMRA

of Turkey (16). Thalassemia is examined in premarital
carrier screening programs in Turkey and is analyzed with
various methods. Among these methods and especially
for nonmolecular methods, confirmation is needed by
use of a molecular test. Some tests can be performed with
specific kits, which are used internationally, but none of
the mutations are specific to any one country. Among the
aforementioned methods, sequence analysis is the gold
standard; however, it is both expensive and impractical.
While real-time PCR can only lead to a result with a
one-step process, sequence analysis involves PCR, post-

PCR purification, and sequencing steps. According to
the current circumstances, our calculations show that the
price of sequence analysis (~295 TL), compared to the
test we used, is more than twice the cost of real-time PCR
(~130 TL).
In this study, we aimed to develop a new, easily
applicable, and reliable screening method for commonly
observed mutations in the Turkish population. This
screening method will save time and expenses prior to
DNA sequencing. Real-time PCR is a preferential method
due to its accuracy, fast and easy applicability, and ability
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Table 3. Real-time PCR results for all patients.

Mutation was
not found

Compound
mutation

HbS
mutation

IVSII M
mutation

IVSI
mutation

Identified mutation

Number of patients

IVSI-1 (G-A) G/A

Heterozygous carriers

6

IVSI-1 (G-A) A/A

Homozygous mutant

1

IVSI-6 (T>C) T/C

Heterozygous carriers

7

IVSI-6 (T>C) C/C

Homozygous mutant

1

IVSI-110 (G>A) G/A

Heterozygous carriers

23

IVSI-110 (G>A)

Homozygous mutant

9

IVSII-1 (G>A) G/A

Heterozygous carriers

8

IVSII-1 (G>A) G/A

Homozygous mutant

2

IVSII-745 (C>G) C/G

Heterozygous carriers

4

IVSII-745 (C>G) G/G

Homozygous mutant

1

HbS (CAG-GTG)

Heterozygous carriers

6

HbS (CAG-GTG)

Homozygous mutant

2

IVSI-1 (G>A) + HbS

Compound heterozygous

2

IVSI-110 (G>A) + IVSII-1 (G>A)

Compound heterozygous

1

Mutation was not found

27

Total patients

100

to provide screening of multiple mutations at once (17).
Another advantage of the real-time PCR method is its
low contamination risk, because the tube covers are
always closed during genotyping (18). For this purpose,
we have designed a real-time PCR kit determining five
β-thalassemia mutations [IVSI-110 (G>A), IVSI-6 (T>C),
IVSII-1(G>A), IVSII-745(C>G), IVSI-1(G>A)] and the
HbS mutation, which causes sickle cell anemia. These six
mutations were included in the test design and account
for 76% of all the β-globin mutations in the Turkish
population (8). We used a housekeeping gene (GAPDH)
as an internal control to make sure that we prepared
adequate and appropriate conditions for amplification, as
well as for understanding the DNA that was added to the
tube. We used non-DNA-containing negative controls in
order to determine the presence of contamination in our
study. We did not observe contamination during any phase
of the study and we preferred the use of TaqMan probes.
Since the TaqMan probe method has relatively easy design
and optimization, it can be easily used both in expression

976

profile extraction and in allelic discrimination (19).
Optimization of our kit was performed with control DNA
samples. These samples consisted of the wild-type and
known mutations. In order to confirm our results, random
selections from our evaluated samples were sent for DNA
sequencing analysis. When comparing sequencing results
to the obtained results from our real-time PCR method, we
observed that all results were compatible when confirming
the accuracy of our method. Some mutations identified
with DNA sequence analysis were not detected with our
developed kit, because they were not included in our panel
(Table 4).
Rapid results are an especially important feature
when defining mutations in at-risk couples that may
require prenatal diagnosis. Therefore, real-time PCR is
an appropriate method for the screening of couples at
increased risk. Obtaining the results on the same day, or
even in a few hours, and setting up PCR and the cycles in
the machine are the primary advantages of this method.
This study allowed us to examine the six most common
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Mutation not found

HbS (GAG-GTG)

IVSII-745 C>G

IVSII-1 G>A

IVSI-6 T>C

IVSI-110 G>A

IVSI- 1 G>A

Table 4. Real-time PCR and sequence analysis results of the selected samples.
Patient No

Real-time PCR analysis results

DNA sequence analysis results

H39

IVSI-1 (G>A) + HbS compound heterozygous

IVSI-1 (G>A) + HbS compound heterozygous

H54

IVSI-1 (G>A) + HbS compound heterozygous

IVSI-1 (G>A) + HbS compound heterozygous

H9

GA heterozygous carriers

GA heterozygous carriers

H50

GA heterozygous carriers

GA heterozygous carriers

H62

AA homozygous mutant

AA homozygous mutant

H11

GA heterozygous carriers

GA heterozygous carriers

H20

GA heterozygous carriers

GA heterozygous carriers

H26

GA heterozygous carriers

GA heterozygous carriers

H29

GA heterozygous carriers

GA heterozygous carriers

H36

AA homozygous mutant

AA homozygous mutant

H78

AA homozygous mutant

AA homozygous mutant

H52

TC heterozygous carriers

TC heterozygous carriers

H67

T/C heterozygous carriers

TC heterozygous carriers

H71

TC heterozygous carriers

TC heterozygous carriers

H73

TC heterozygous carriers

TC heterozygous carriers

H89

CC homozygous mutant

CC homozygous mutant

H18

GA heterozygous carriers

GA heterozygous carriers

H37

GA heterozygous carriers

GA heterozygous carriers

H38

GA heterozygous carriers

GA heterozygous carriers

H46

AA homozygous mutant

AA homozygous mutant

H48

GA heterozygous carriers

GA heterozygous carriers

H16

CG heterozygous carriers

CG heterozygous carriers

H31

CG heterozygous carriers

CG heterozygous carriers

H65
H95
H96

CG heterozygous carriers
CG heterozygous carriers
GG homozygous mutant

CG heterozygous carriers
CG heterozygous carriers
GG homozygous mutant

H24

AT heterozygous carriers

AT heterozygous carriers

H25

AT heterozygous carriers

AT heterozygous carriers

H10

AT heterozygous carriers

AT heterozygous carriers

H54

IVSI-1 (G>A) + HbS compound heterozygous

IVSI-1 (G>A) + HbS compound heterozygous

H64

TT homozygous mutant

TT homozygous mutant

H4

Mutation was not found

Codon 15 GA heterozygous carriers

H14

Mutation was not found

Codon 39 CT heterozygous carriers

H15

Mutation was not found

Codon 39 CT heterozygous carriers

H34

Mutation was not found

IVSII-848 CA heterozygous carriers

H35
H85

Mutation was not found
Mutation was not found

HbD (Punjab) (Glu121Gln) heterozygous carriers
IVSII-848 AA homozygous mutant

β-globin mutations encountered in the Turkish population
simultaneously and in a brief interval of 1–1.5 h.
In conclusion, in this study we designed a reliable
β-globin screening kit that includes 76% of the mutations

observed in Turkey. This kit can be used not only for
β-thalassemia screening but also as a fast, simple, and
inexpensive molecular diagnostic method.
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